Respiree Extends Series A Funding to Expand Global Team and US Presence

The company plans to use the expanded funding to grow its global commercial team and strengthen its presence in the United States, where it is expanding from the Texas Medical Center (TMC) Innovation in Houston.

What is Respiree?

Respiree is a health tech company developing AI and machine learning platforms for managing disease progression across the healthcare continuum.

Its 1Bio platform uses data from electronic health records (EHRs) along with Respiree's proprietary US-patented and FDA-cleared sensors. The platform is designed to measure and track disease progression over time.

Respiree currently operates across the United States, Australia, and the Asia-Pacific (APAC) region. Its technology has received CE marking, regulatory clearance from Australia's Therapeutic Goods Administration (TGA), and 510(k) clearance from the US Food and Drug Administration (FDA).

Funding Details

Respiree's latest funding is an extension of its Series A round. We Venture Capital and ClavystBio are leading the round.

The expanded Series A includes new participation from ARKRAY & PARTNERS Pte. Ltd. (AAP) and Bizedge Capital. Previously announced investors include Adaptive Capital Partners, Greenwillow Capital Management, Seeds Capital, and One Six 8 Ventures.

The company has not disclosed the total amount raised in the latest extension.

How Will Respiree Use the Funding?

Respiree will use the new capital to continue expanding its global commercial team and accelerate its growth in the United States.

The company is building its US presence from Houston's Texas Medical Center (TMC) Innovation, while continuing its broader international expansion.

Who Founded Respiree

Respiree is headquartered in Singapore and is led by Founder and CEO Dr. Gurpreet Singh.

The company develops AI/ML-based healthcare technology focused on disease progression management. Its 1Bio platform combines EHR data with proprietary sensors to provide longitudinal tracking of disease progression.

Respiree's technology is available in the US, Australia, and APAC. It holds CE marking and has received regulatory clearances from Australia's TGA and the US FDA.

Market and Business Growth

Respiree is expanding its commercial operations across international healthcare markets. The addition of AAP and Bizedge Capital to its Series A syndicate gives the company additional investors as it continues its global growth plans.

Its US operations are being developed from Houston, with the company using the Texas Medical Center Innovation ecosystem as part of its expansion.

What Happens Next?

Respiree will focus on expanding its global commercial team and strengthening its presence in the US market. The company will also continue developing and deploying its AI-based disease progression management platform across its existing international markets.

Read Also - Bonbon Mobility Raises $500,000 in Pre-Seed Round to Expand Car-Care Network